Cyclacel Historical Financial Ratios
| CYCC Stock | USD 0.40 0.01 2.56% |
Cyclacel Pharmaceuticals is presently reporting on over 106 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0929, PTB Ratio of 3.93 or Days Sales Outstanding of 973 will help investors to properly organize and evaluate Cyclacel Pharmaceuticals financial condition quickly.
Cyclacel |
About Cyclacel Financial Ratios Analysis
Cyclacel PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cyclacel Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cyclacel financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cyclacel Pharmaceuticals history.
Cyclacel Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Cyclacel Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cyclacel Pharmaceuticals sales, a figure that is much harder to manipulate than other Cyclacel Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Cyclacel Pharmaceuticals dividend as a percentage of Cyclacel Pharmaceuticals stock price. Cyclacel Pharmaceuticals dividend yield is a measure of Cyclacel Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an Cyclacel Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Cyclacel Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cyclacel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.At present, Cyclacel Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 0.75, whereas Price To Sales Ratio is forecasted to decline to 5.91.
| 2023 | 2024 (projected) | Dividend Yield | 0.0885 | 0.0929 | Price To Sales Ratio | 6.22 | 5.91 |
Cyclacel Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Cyclacel Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclacel Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Dividend Yield | 0.0184 | 0.007083 | 0.005789 | 0.0305 | 0.0885 | 0.0929 | |
| Ptb Ratio | 7.19 | 0.93 | 0.85 | 0.42 | 3.74 | 3.93 | |
| Book Value Per Share | 215.0 | 137.31 | 62.62 | 23.58 | 0.71 | 0.75 | |
| Free Cash Flow Yield | (0.86) | (0.28) | (0.53) | (3.17) | (7.1) | (6.74) | |
| Operating Cash Flow Per Share | (173.64) | (32.75) | (31.16) | (31.67) | (18.94) | (19.88) | |
| Capex To Depreciation | 0.5 | 4.8 | 0.63 | 0.22 | 0.19 | 0.18 | |
| Pb Ratio | 7.19 | 0.93 | 0.85 | 0.42 | 3.74 | 3.93 | |
| Free Cash Flow Per Share | (173.83) | (33.15) | (31.2) | (31.68) | (18.94) | (19.89) | |
| Roic | (0.71) | (0.28) | (0.51) | (1.46) | (37.02) | (35.16) | |
| Inventory Turnover | 0.0284 | 0.0292 | 0.0745 | (0.005674) | (0.006525) | (0.006199) | |
| Net Income Per Share | (143.88) | (34.86) | (31.74) | (32.23) | (26.51) | (27.84) | |
| Days Of Inventory On Hand | 51.37 | 12.8K | 4.9K | (64.3K) | (74.0K) | (70.3K) | |
| Payables Turnover | 0.0225 | 0.0389 | 0.0203 | 0.0125 | 0.0144 | 0.0137 | |
| Cash Per Share | 218.45 | 137.91 | 61.44 | 27.9 | 3.97 | 3.77 | |
| Pocfratio | (1.16) | (3.58) | (1.87) | (0.32) | (0.14) | (0.15) | |
| Payout Ratio | (0.0257) | (0.0238) | (0.0106) | (0.009482) | (0.008912) | (0.009357) | |
| Capex To Operating Cash Flow | (0.001059) | (0.0121) | (0.001456) | (3.36E-4) | (3.72E-4) | (3.91E-4) | |
| Pfcf Ratio | (1.16) | (3.53) | (1.87) | (0.32) | (0.14) | (0.15) | |
| Days Payables Outstanding | 16.2K | 9.4K | 18.0K | 29.2K | 26.3K | 27.6K | |
| Roe | (0.67) | (0.25) | (0.51) | (1.37) | (37.16) | (35.3) | |
| Ev To Operating Cash Flow | (0.0256) | 0.5 | 0.0974 | 0.56 | 0.0664 | 0.0697 | |
| Pe Ratio | (1.4) | (3.36) | (1.84) | (0.31) | (0.1) | (0.11) | |
| Return On Tangible Assets | (0.51) | (0.23) | (0.44) | (0.77) | (2.56) | (2.43) | |
| Ev To Free Cash Flow | (0.0255) | 0.49 | 0.0973 | 0.56 | 0.0663 | 0.0697 | |
| Earnings Yield | (0.72) | (0.3) | (0.54) | (3.22) | (9.93) | (9.43) | |
| Net Debt To E B I T D A | 1.11 | 3.05 | 1.61 | 0.66 | 0.13 | 0.12 | |
| Current Ratio | 5.79 | 14.27 | 7.73 | 3.3 | 0.91 | 0.87 | |
| Tangible Book Value Per Share | 215.0 | 137.31 | 62.62 | 23.58 | 0.71 | 0.75 | |
| Graham Number | 834.29 | 328.19 | 211.46 | 130.79 | 20.63 | 19.6 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.40) | Revenue Per Share 0.044 | Quarterly Revenue Growth (0.99) | Return On Assets (1.03) | Return On Equity (5.71) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.